Caris Life Sciences,�Inc. (CAI)
(Delayed Data from NSDQ)
$30.30 USD
+0.81 (2.75%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $30.27 -0.03 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CAI 30.30 +0.81(2.75%)
Will CAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CAI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CAI
Caris Life Sciences Inc (CAI) Unveils Breakthrough AI Tool for Cancer Diagnosis | CAI stock news
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin ...
ClearBridge Select Strategy Q2 2025 Commentary
Caris Life Sciences Inc (CAI) to Announce Q2 2025 Financial Results | CAI stock news
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025 | CAI ...